Lupus & antiphospholipid syndrome
Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study
Authors' conclusion
Most patients experienced lupus low disease activity state, reduced flare rate and glucocorticoid demand, and a stable SDI trend after belimumab treatment initiation.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) treated with belimumab, single centre
- Participants
- 92 patients
- Exposure
- Before vs after belimumab treatment initiation
- Belimumabn = 92
- Outcome
- Changes in flare-free rate, LLDAS attainment rate, GC dosage, SLICC/ACR DI (SDI) score and drug retention rate after treatment initiation
Methodological detailssingle-center
- Single-center
Main finding
As reported in the abstract
Flare rate, before vs 52 weeks after initiating belimumab
- Flare rate decreased from 82.6% to 14.1%
- p < .01
Observational data: associations, not effects.
Further findings
LLDAS attainment · week 52 and 1000 days
- Patients attaining LLDAS until week 52
- > 70%
- Patients attaining LLDAS until 1000 days
- ∼90%
GC dosage (prednisolone, mg/d)
- Initiation day
- 8.88 (6.00-15.00) mg/d
- Week 52
- 5.00 (2.00-7.00) mg/d
- Final day of study period
- 3.00 (0.46-6.06) mg/d
- Initiation day vs week 52
- P < 0.01
- Initiation day vs final day
- P < 0.01
- Required ≤5 mg/d prednisolone at end of study
- 68.5%
- Discontinued GC
- 22.8%
SDI progression-free
- Week 52
- ∼95%
- Day 1000
- ∼90%
Drug retention rate
- Week 52
- 90%
- Day 1000
- > 80%
Original publication
Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study. Lupus. Published 19 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →